Tempus Revenue and Competitors

Location

$1.1B

Total Funding

Finance

Industry

Estimated Revenue & Valuation

  • Tempus's estimated annual revenue is currently $34.4M per year.(i)
  • Tempus's estimated revenue per employee is $231,000
  • Tempus's total funding is $1.1B.
  • Tempus's current valuation is $8.1B.

Employee Data

  • Tempus has 149 Employees.(i)
  • Tempus grew their employee count by -2% last year.

Tempus's People

NameTitleEmail/Phone
1
CTOReveal Email/Phone
2
VP Trading & DealingReveal Email/Phone
3
VP OF MARKETINGReveal Email/Phone
4
Chief Compliance OfficerReveal Email/Phone
5
Director Pathology and Medical Lab OperationsReveal Email/Phone
6
Chief Strategy OfficerReveal Email/Phone
7
Executive DirectorReveal Email/Phone
8
Senior Systems ManagerReveal Email/Phone
9
Operations SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$33.3M95-2%N/AN/A
Add Company

What Is Tempus?

Tempus helps corporate clients navigate global currency markets by combining unparalleled market insight, competitive rates of exchange and unmatched personalized service. We serve thousands of corporate clients by offering these key differentiated features:

keywords:N/A

$1.1B

Total Funding

149

Number of Employees

$34.4M

Revenue (est)

-2%

Employee Growth %

$8.1B

Valuation

N/A

Accelerator

Tempus News

2022-04-17 - Tempus Fugit | Community | idahocountyfreepress.com

10 YEARS AGO. April 18, 2012. · In the May 15 Republican primary election for Dist. 1 Idaho County Commissioner position, incumbent R.

2022-04-13 - Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion ...

NEW YORK – Pyramid Biosciences said Tuesday that it will join Tempus' TIME Trial Network for clinical trial patient identification under a...

2022-04-13 - Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors

Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors. April 12, 2022 ·2 min read.

2020-12-10 - Google joins $200M round for Tempus, now valued at $8B

Cancer treatment startup Tempus has raised another mega-round of venture capital funding as it continues to grow as Chicago’s most valuable startup. Tempus raised $200 million in a Series G-2 financing round that included Google, a first-time Tempus investor. Existing investors Baillie Gifford, ...

2020-03-17 - Tempus: $100 Million Funding And $5 Billion Valuation

Chicago-based health tech company Tempus announced it raised $100 million in Series G funding at a post-money valuation of $5 billion Tempus, a Chicago-based health tech company founded by serial entrepreneur Eric Lefkofsky, announced it raised $100 million in Series G funding at a post-money v ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53.3M149N/AN/A
#2
$15M1491%N/A
#3
$22.4M1493%$49.9M
#4
$36.1M1498%N/A
#5
$36.1M149N/AN/A